Toshiyasu Sakane

Dr. Toshiyasu Sakane


Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 January 2018 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
ATAkiko Tanaka
Akiko Tanaka
TFTomoyuki Furubayashi
Tomoyuki Furubayashi
MAMari Arai
Mari Arai
Daisuke InoueDaisuke Inoue
Daisuke Inoue
SKShunsuke Kimura
Shunsuke Kimura
AYAkira Yamamoto
Akira Yamamoto

17 January 2020 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Tomoyuki FurubayashiTomoyuki Furubayashi
Tomoyuki Furubayashi
Daisuke InoueDaisuke Inoue
Daisuke Inoue
NNNoriko Nishiyama
Noriko Nishiyama
ATAkiko Tanaka
Akiko Tanaka
RYReiko Yutani
Reiko Yutani
TSToshiyasu Sakane
Toshiyasu Sakane
Recently, various types of cultured cells have been used to research the mechanisms of transport and metabolism of drugs. Although many studies using cultured cell systems have been published, a comparison of different cultured cell systems has never been reported. In this study, Caco-2, Calu-3, Madin–Darby canine kidney (MDCK), EpiAirway and MucilAir were used as popular in vitro cell culture systems, and the permeability of model compounds across these cell systems was evaluated to compare barrier characteristics and to clarify their usefulness as an estimation system for nasal drug absorption in rats. MDCK unexpectedly showed the best correlation (r = 0.949) with the fractional absorption (Fn) in rats. Secondly, a high correlation was observed in Calu-3 (r = 0.898). Also, Caco-2 (r = 0.787) and MucilAir (r = 0.750) showed a relatively good correlation with Fn. The correlation between Fn and permeability to EpiAirway was the poorest (r = 0.550). Because EpiAirway forms leakier tight junctions than other cell culture systems, the paracellular permeability was likely overestimated with this system. On the other hand, because MDCK formed such tight cellular junctions that compounds of paracellular model were less likely permeated, the paracellular permeability could be underestimated. Calu-3, Caco-2 and MucilAir form suitable cellular junctions and barriers, indicating that those cell systems enable the precise estimation of nasal drug absorption.

4 November 2018 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
CNChihiro Naito
Chihiro Naito
HKHidemasa Katsumi
Hidemasa Katsumi
TSTomoko Suzuki
Tomoko Suzuki
YQYing-Shu Quan
Ying-Shu Quan
FKFumio Kamiyama
Fumio Kamiyama
AYAkira Yamamoto
Akira Yamamoto
Human parathyroid hormone (1-34) (PTH) has been widely used as the subcutaneous injection formulation for the treatment of osteoporosis. In the present study, we developed an efficient transdermal delivery system of PTH by using dissolving microneedle arrays (MNs) composed of hyaluronic acid (HA) for the treatment of osteoporosis. PTH-loaded MNs, with needle length 800 µm, were fabricated via a micro-molding method. The stability of PTH in MNs was found to be 6-fold higher than that of PTH solution when stored at room temperature (15–20 °C) for one month. Micron-scale pores were clearly visible in rat skin following application of PTH-loaded MNs. PTH-loaded MNs were completely dissolved by 60 min following application to rat skin. The bioavailability (BA) of PTH relative to subcutaneous injection was 100 ± 4% following application of PTH-loaded MNs in rats. In addition, PTH-loaded MNs were found to effectively suppress decreases in bone density in a rat model of osteoporosis. Furthermore, no skin irritation was observed at the site of application in rats. These findings indicate that our dissolving MNs have a potential use in formulations for the transdermal delivery of PTH and for the treatment of osteoporosis.


1 August 2015 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
MAMasashi Adachi
Masashi Adachi
YHYuta Hinatsu
Yuta Hinatsu
KKKosuke Kusamori
Kosuke Kusamori
HKHidemasa Katsumi
Hidemasa Katsumi
TSToshiyasu Sakane
Toshiyasu Sakane
AYAkira Yamamoto
Akira Yamamoto

1 January 2017 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
ATAkiko Tanaka
Akiko Tanaka
TFTomoyuki Furubayashi
Tomoyuki Furubayashi
MTManami Tomisaki
Manami Tomisaki
MKMayuko Kawakami
Mayuko Kawakami
SKShunsuke Kimura
Shunsuke Kimura
AYAkira Yamamoto
Akira Yamamoto